Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.70 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581954 | 0.91 | HDAC1 (0.70) | KCNH2HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL4578417 | 0.90 | HDAC1 (0.69) | KCNH2HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1068434 | 0.89 | HDAC1 (0.71) | KCNH2HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1067590 | 0.89 | HDAC3 (0.76) | KCNH2HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL4579014 | 0.88 | HDAC1 (0.67) | KCNH2HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL20181654 | 0.87 | HDAC3 (0.81) | KCNH2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL1931182 | 0.86 | HDAC1 (0.65) | KCNH2HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL20181475 | 0.86 | KCNH2 (1.00) | KCNH2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL23960888 | 0.85 | HDAC3 (0.73) | KCNH2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL4579757 | 0.85 | HDAC1 (0.64) | KCNH2HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | claimed |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | disclosed |
| CN-101466670-A | Benzamide derivatives as inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2009-06-24 | — | — | CN | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | KCNH2 3509/4885HDAC3 7/4885HDAC1 1/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | KCNH2 3232/4885HDAC3 8/4885HDAC1 1/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 4371/4885HDAC3 6/4885HDAC1 1/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | KCNH2 3225/4885HDAC3 7/4885HDAC1 1/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 3551/4885HDAC3 7/4885HDAC1 1/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 4371/4885HDAC3 6/4885HDAC1 1/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | KCNH2 4025/4885HDAC3 3/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.